Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide
CNS Drugs · 2025-08 · 39 (8) · 763-777
DOI: 10.1007/s40263-025-01202-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 01.07.2025. Verfasst von Veerle Bergink und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Room L4-34, New York, NY, 10029, USA. Veerle.bergink@mssm.edu. Hauptthemen laut MEDLINE: Bipolar Disorder, Pregnancy Complications, Antimanic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIMH NIH HHS, NIMH.
Abstract (Originalsprache)
Medication management in women with bipolar disorder (BD) in the perinatal period is challenging, given that many patients taper or stop medication during pregnancy, and the postpartum period is an extremely high-risk period for relapse. The objective of this narrative review was to investigate the perinatal efficacy as well as potential adverse effects on the child of common treatments for bipolar disorder. These treatments include lithium, lamotrigine, other antiepileptics, quetiapine, olanzapine, aripiprazole, other antipsychotics, antidepressants, benzodiazepines, Z-drugs, and other sleep medication. Despite the worldwide decline in lithium use, it remains the gold standard for acute and maintenance treatment of BD, and we continue to advise its use in women of reproductive age. In contrast, medications with a high risk for teratogenicity such as valproate and carbamazepine should be avoided in women of childbearing potential. Women with bipolar disorder are at very high risk of relapse after delivery, but this risk is more than twofold lower with adequate pharmacological prophylaxis. We advise to make a written perinatal bipolar relapse prevention plan in collaboration with the patient, family, and healthcare professionals, which includes a description of: (1) maintenance treatment during pregnancy, (2) preferred mode of delivery, (3) medication immediately after delivery and the first months postpartum for relapse prevention, (4) preferred plan for feeding (breast-feeding versus bottle-feeding), (5) strategies to assist women in ensuring adequate sleep and stable circadian rhythm in the first weeks after delivery, and (6) how to recognize the first symptoms of relapse and which intervention strategies to take.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Room L4-34, New York, NY, 10029, USA. Veerle.bergink@mssm.edu.
- Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands. Veerle.bergink@mssm.edu.
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Room L4-34, New York, NY, 10029, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
- Department of Psychiatry and Behavioral Sciences, Northwell Health Staten Island University Hospital, Staten Island, NY, USA.
ORCID-Profile: Veerle Bergink, Mariella Suleiman, Mary-Anne Hennen, Thalia Robakis
Förderung
- NIMH NIH HHS
- NIMH
Zitieren
APA
Bergink, V., Suleiman, M., Hennen, M. A., & Robakis, T. (2025). Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide. CNS Drugs, 39(8), 763-777. https://doi.org/10.1007/s40263-025-01202-7
Vancouver
Bergink V, Suleiman M, Hennen MA, Robakis T. Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide. CNS Drugs. 2025;39(8):763-777. doi:10.1007/s40263-025-01202-7
BibTeX
@article{Bergink2025,
author = {Bergink, Veerle and Suleiman, Mariella and Hennen, Mary-Anne and Robakis, Thalia},
title = {Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide},
journal = {CNS Drugs},
year = {2025},
volume = {39},
number = {8},
pages = {763--777},
doi = {10.1007/s40263-025-01202-7}
}
EUVIMED